Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2009 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (308)	10/23/2009 6:48:39 PM
From: BulbaMan	Read Replies (1) \| Respond to of 418

10/23/09 update Despite a bunch of better-than-expected earnings reports, the Dow once again closed the week below the totemic Dow 10,000 mark. And although the Nasdaq Composite Index closed about even for the week, biotechs were hit especially hard. At Friday's close, the NCI was up 37.09% CYTD, or Contest Year To Date, (vs. up 37.24% CYTD a week ago), while the Nasdaq Biotech Index was up 10.95% CYTD (vs. up 16.47% CYTD a week ago) and the Contest median was up 12.65% CYTD (vs. up 21.23% CYTD a week ago). Unsurprisingly, RKRW's portfolio remained in the top spot with GENE's portfolio in the No. 2 position. Close behind, NIGEL's portfolio and GEORGIA's portfolio placed third & fourth. The week's closing CYTD percentages are: RKRW up 112.85%, GENE up 67.69%, NIGEL up 64.59% and GEORGIA up 64.29%. At Friday's close, 22 of the 32 Contest portfolios were in the black and 17 of the 32 were beating the NBI. Portfolio adjustments: Given the various buyouts throughout the year, including multiple buyouts in some portfolios, the reallocation of buyout cash has become quite complex. The reallocations are also likely to be less meaningful as we approach the end of the Contest year. So, unless contestants strongly object, my inclination is to end further reallocations and just leave cash from future buyouts in portfolios until the Contest is over. (If it's a really close call for first place and any of the contenders had buyouts after 10/23, I will check to see if reallocations would have changed the winner.) This week's portfolio adjustments are: 1) PPHM does 1-5 reverse split with temporary symbol change to PPHMD. 2) SEPR buyout at $23 per share. I reallocated cash using the 10/23/09 closing prices. Have a terrific weekend biotechies! Below is the Top Ten list on 10/23/09: 10/23/09 Rank Name Profit/Loss 1 RKRW 112,852 2 GENE 67,687 3 NIGEL 64,587 4 GEORGIA 64,291 5 BULBA 57,976 6 MIKE 56,015 7 ASHLEY 54,287 8 BIOFISH 53,441 9 ENZYME 42,492 10 PGO 31,803 (All corrections, especially adjustments for splits, greatly appreciated.)